Company / Shareholders' Equity
Niagen Bioscience, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$76.5M
FY2025
5-year range
$16.4M / $76.5M
FY2021-FY2025
Trend
+169.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity returned to growth in FY2025 after 2 years of decline, reaching $77M.
Based on SEC 10-K filings.
$77M in FY2025 with a 5-year CAGR of +30.2%.
Improved from $29M to $77M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +34.1%
- 5-Year CAGR
- +30.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +30.2%, indicating consistent growth.
- In FY2025, shareholders' equity increased 169.0% year-over-year.
- Lowest shareholders' equity in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $76.5M | +169.0% |
| FY2024 | $28.5M | -0.8% |
| FY2023 | $28.7M | -9.6% |
| FY2022 | $31.7M | +93.2% |
| FY2021 | $16.4M | -19.7% |
| FY2020 | $20.4M | +0.0% |
| FY2019 | $20.4M | -62.0% |
| FY2018 | $53.8M | +0.0% |
| FY2017 | $53.8M | +439.7% |
| FY2016 | $10.0M | +89.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026